<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04357899</url>
  </required_header>
  <id_info>
    <org_study_id>33_20B</org_study_id>
    <nct_id>NCT04357899</nct_id>
  </id_info>
  <brief_title>Stroke Research Consortium in Northern Bavaria (STAMINA)</brief_title>
  <acronym>STAMINA</acronym>
  <official_title>Stroke Research Consortium in Northern Bavaria - STAMINA, a Multicenter Longitudinal Cohort Study on Ischemic Stroke Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Each year, approximately 15 million people suffer a stroke worldwide of which 80% are due to
      ischemic cerebral infarction. Based on the results of randomized controlled trials, treatment
      options and patient outcomes in acute ischemic stroke have dramatically improved in recent
      years. However, these advances in thrombolysis and endovascular therapy need to be
      established outside controlled trials to optimize stroke management, treatment procedures,
      patient selection and inter-hospital transfer in clinical practice. This multicenter
      longitudinal cohort study is based on a large stroke care network in Northern Bavaria,
      Germany (region of more than 3.5 million inhabitants) to evaluate and improve treatment in
      ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods: This multicenter longitudinal cohort study will include ischemic stroke patients
      treated within a telemedical stroke care network and patients transferred to tertiary stroke
      centers for treatment procedures from hospitals outside the telemedical network. Individual
      patient data are available from two tertiary stroke centers and 24 primary and secondary
      stroke facilities in Northern Bavaria, Germany. Patients with ischemic stroke transferred to
      the tertiary stroke centers for treatment procedures - i.e. endovascular therapy or
      thrombolysis in stroke with an unknown time of onset - and all stroke patients with either
      large vessel occlusion (LVO) and/or thrombolysis therapy admitted to the University Hospital
      Erlangen will be integrated from institutional prospective stroke registries. Consecutive
      patients admitted between January 2006 and December 2019 will be included, an estimated total
      number of more than 3000 ischemic stroke patients - approximately 1000 patients with LVO
      receiving endovascular therapy, 1000 patients with LVO not receiving endovascular therapy and
      1000 patients without LVO receiving thrombolysis therapy.

      Demographic and clinical data including medical history, medication and laboratory results
      will be obtained by review of medical charts, institutional databases or prospective
      registries, supplemented by structured interviews on follow-up information or by review of
      all available medical records. In detail the following parameters will be evaluated: prior
      medical history (e.g. comorbidities, premorbid functional status, medication), admission
      status (e.g. NIHSS, GCS, body temperature, arterial blood pressure), cerebral imaging
      parameters (e.g. Alberta Stroke Program Early CT score [ASPECTS], perfusion volumes, mismatch
      and collateral status on admission imaging, final infarct volume on follow-up imaging),
      treatment procedures (e.g. intravenous thrombolysis, endovascular therapy, decompressive
      surgery), time intervals (e.g. symptom onset or last seen normal until admission, imaging,
      thrombolysis, groin puncture, recanalization), complications (e.g. hemorrhagic
      transformation, arterial dissection, distant ischemic stroke), laboratory parameters,
      clinical and diagnostic follow-up (e.g. neurological status, blood pressure, vascular
      ultrasound), stroke etiology, secondary prevention (e.g. lipid lowering medication,
      antiplatelet therapy, anticoagulation) and clinical outcomes (e.g. mortality, modified Rankin
      Scale).

      Ethics Approval: The study was approved by the Institutional Review Board of the
      Friedrich-Alexander-Universität Erlangen-Nürnberg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2006</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Outcome (modified Rankin Scale 0-6)</measure>
    <time_frame>at day 90</time_frame>
    <description>The Distribution of Scores on the modified Rankin Scale (mRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Independence (modified Rankin Scale 0-2)</measure>
    <time_frame>at day 90</time_frame>
    <description>Proportion of participants with functional independence (mRS 0-2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Favorable Outcome (modified Rankin Scale 0-1)</measure>
    <time_frame>at day 90</time_frame>
    <description>Proportion of participants with favorable outcome (mRS 0-1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infarct volume</measure>
    <time_frame>at day 5 (±2)</time_frame>
    <description>Infarct volume on CT or diffusion-weighted MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lesion growth volume</measure>
    <time_frame>at day 5 (±2)</time_frame>
    <description>Lesion growth volume between ischemic core on baseline imaging and infarkt volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intracranial hemorrhage</measure>
    <time_frame>at 24 (±6) hours</time_frame>
    <description>Rate of intracranial hemorrhage defined according to different criteria (ECASS II, SITS-MOST, NINDS or Parenchymal hemorrhage Type 2) on the 24 hour scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recanalization Rates</measure>
    <time_frame>at 24 (±6) hours</time_frame>
    <description>Recanalization of the primary arterial occlusive lesion (based on ultrasound, clinical and radiological assessment) at 24-hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>at 90 days</time_frame>
    <description>All cause mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time</measure>
    <time_frame>procedure</time_frame>
    <description>Time from groin puncture to first recanalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Door-to-groin puncture time</measure>
    <time_frame>until 24 hours after admission to the tertiary stroke center or until hospital discharge, whichever came first</time_frame>
    <description>Time from arrival at the tertiary stroke center to groin puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Door-to-needle time</measure>
    <time_frame>until 24 hours after admission to the tertiary stroke center or until hospital discharge, whichever came first</time_frame>
    <description>Time from hospital arrival to IVT administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom-to-door time</measure>
    <time_frame>until 24 hours after admission to the tertiary stroke center or until hospital discharge, whichever came first</time_frame>
    <description>Time from symptom onset to arrival at the first hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interhospital transfer time</measure>
    <time_frame>until 24 hours after admission to the tertiary stroke center or until hospital discharge, whichever came first</time_frame>
    <description>Time from arrival at the first hospital to arrival at the tertiary stroke center</description>
  </secondary_outcome>
  <enrollment type="Actual">3769</enrollment>
  <condition>Ischemic Stroke</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thrombolysis therapy</intervention_name>
    <other_name>thrombolytic drugs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endovascular therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>decompressive surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>multimodal imaging in acute ischemic stroke</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transfer of acute stroke patients to tertiary stroke centers</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>initiation of antiplatelets, oral anticoagulation and lipid lowering drugs for secondary prevention</intervention_name>
    <other_name>antithrombotic oder lipid lowering drugs</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Ischemic stroke patients treated within a stroke care network in Northern Bavaria, Germany.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical signs and symptoms consistent with the diagnosis of an acute ischemic stroke

          -  Presence of large vessel occlusion (as evidenced by CTA, MRA or DSA) and/or
             intravenous thrombolysis therapy applied

        Exclusion Criteria:

          -  Age &lt; 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Schwab</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Department of Neurology, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnd Dörfler</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Department of Neuroradiology, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hagen B Huttner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Department of Neurology, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tobias Engelhorn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Department of Neuroradiology, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernd Kallmünzer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Department of Neurology, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maximilian I Sprügel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Department of Neurology, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Department of Neurology</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Erlangen-Nürnberg Medical School</investigator_affiliation>
    <investigator_full_name>Hagen B. Huttner</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Thrombolysis</keyword>
  <keyword>Mechanical thrombectomy</keyword>
  <keyword>Endovascular procedure</keyword>
  <keyword>Stroke</keyword>
  <keyword>Cerebrovascular Disorders</keyword>
  <keyword>Brain Diseases</keyword>
  <keyword>Brain Ischemia</keyword>
  <keyword>Cerebral Infarction</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Tissue Plasminogen Activator</keyword>
  <keyword>Fibrinolytic Agents</keyword>
  <keyword>Fibrin Modulating Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypolipidemic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Because of local ethics committees restrictions the final decision upon release of the raw data has not been made.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

